You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR MANNITOL 15% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MANNITOL 15% IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003062 ↗ Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1997-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed Johns Hopkins University Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed National Center for Research Resources (NCRR) Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956 ↗ Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed Massachusetts General Hospital Phase 2/Phase 3 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00111956 ↗ Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2/Phase 3 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00113854 ↗ Mannitol as Adjunct Therapy for Childhood Cerebral Malaria Unknown status Makerere University Phase 3 2004-10-01 Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection in African children and nonimmune travellers despite availability of quinine, the current drug of choice. Several reports have suggested that raised intracranial pressure (ICP) is a major cause of death among children with cerebral malaria. Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post traumatic raised ICP. There have been some case reports of reduction in mortality and morbidity in African children with cerebral malaria following administration of mannitol, but as these were not randomized controlled trials it is difficult to evaluate their significance. This study seeks to establish whether a single dose of intravenous mannitol given to children with cerebral malaria will significantly reduce the coma recovery time.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MANNITOL 15% IN PLASTIC CONTAINER

Condition Name

Condition Name for MANNITOL 15% IN PLASTIC CONTAINER
Intervention Trials
Asthma 20
Cystic Fibrosis 10
Healthy 7
Traumatic Brain Injury 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MANNITOL 15% IN PLASTIC CONTAINER
Intervention Trials
Asthma 23
Intracranial Hypertension 12
Cystic Fibrosis 10
Brain Neoplasms 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MANNITOL 15% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for MANNITOL 15% IN PLASTIC CONTAINER
Location Trials
United States 137
Canada 38
United Kingdom 35
Australia 34
Italy 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for MANNITOL 15% IN PLASTIC CONTAINER
Location Trials
New York 19
Massachusetts 12
Minnesota 9
Oregon 8
Ohio 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MANNITOL 15% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for MANNITOL 15% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 37
Phase 3 33
Phase 2/Phase 3 10
[disabled in preview] 83
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MANNITOL 15% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Completed 132
Unknown status 27
Not yet recruiting 16
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MANNITOL 15% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for MANNITOL 15% IN PLASTIC CONTAINER
Sponsor Trials
Pharmaxis 19
Northwell Health 7
National Cancer Institute (NCI) 6
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MANNITOL 15% IN PLASTIC CONTAINER
Sponsor Trials
Other 363
Industry 64
NIH 17
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.